mianserin has been researched along with Schizophrenia in 46 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine has often been prescribed as add-on treatment for schizophrenia in patients with suboptimal response to conventional treatments." | 9.22 | Mirtazapine in schizophrenia - an undeservedly overlooked option? ( Joffe, G; Terevnikov, V, 2022) |
| " In this study, interrelationship of similar metabolic effects of mirtazapine and its earlier reported desirable effects on psychopathology in first-generation antipsychotics (FGAs)-treated schizophrenia were explored." | 9.17 | Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial. ( Burkin, M; Chukhin, E; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2013) |
| "We aimed to evaluate predictors and mediators of enhancing effect of adjunctive mirtazapine on cognition in schizophrenia." | 9.17 | Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation. ( Burkin, M; Chukhin, E; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2013) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 9.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| "Schizophrenia-diagnosed patients with a prolonged disease and a history of a poor response to numerous antipsychotics, who were at least moderately ill despite their FGAs treatment, received add-on mirtazapine (n=20) or placebo (n=19) in a 6-week double-blind randomized controlled trial (RCT)." | 9.14 | Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2009) |
| "This trial does not confirm previous research supporting the use of mirtazapine adjunctive to atypical antipsychotic treatment for schizophrenia." | 9.14 | Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. ( Berk, M; Bole, F; D'Souza, R; Dodd, S; Gama, CS; Hustig, H; Koopowitz, L; Malloy, H; Monkhouse, A; Piskulic, D; Rowland, C; Sathiyamoorthy, S; Sundram, S, 2009) |
| "Mirtazapine added to antipsychotics appears to improve the clinical picture of schizophrenia, including both negative and positive symptoms." | 9.14 | Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2010) |
| "It has been reported that mirtazapine would be helpful for treating negative symptoms in schizophrenia." | 9.14 | The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. ( Abbasi, SH; Akhondzadeh, S; Behpournia, H; Ghoreshi, A; Raznahan, M; Rezaei, F; Rezazadeh, SA; Salehi, B, 2010) |
| "These findings support our previous data on the additive antipsychotic effect of mirtazapine in FGAs-treated schizophrenia." | 9.14 | More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2010) |
| " In a double-blind placebo-controlled study we examined the effect of add-on mianserin (15 mg/day), an agent with marked 5-HT2A antagonism, on cognitive functioning in 30 chronic hospitalized DSM-IV schizophrenia patients stabilized on typical antipsychotics." | 9.10 | Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. ( Fuchs, C; Gonopolsky, I; Koren, D; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia." | 9.08 | Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. ( Fujikawa, T; Furutani, M; Hayashi, T; Horiguchi, J; Nishikawa, T; Takahashi, T; Tawara, Y; Yamawaki, S; Yano, T; Yokota, N, 1997) |
| "All randomised-controlled trials (RCTs) with useable data focusing on mirtazapine adjunct for people with schizophrenia." | 8.98 | Mirtazapine adjunct for people with schizophrenia. ( Perry, LA; Ramson, D; Stricklin, S, 2018) |
| "To assess the efficacy of mirtazapine as an adjunctive treatment of negative symptoms in patients with chronic schizophrenia via meta-analysis." | 8.91 | Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia. ( Chiapelli, J; Fischer, BA; Himelhoch, S; Reese, C; Vidal, C, 2015) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 7.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| "This study randomly assigned FGA-treated patients with schizophrenia to receive either an add-on mirtazapine (n = 20) or a placebo (n = 19) for 6 weeks." | 7.85 | Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics. ( Burkin, M; Joffe, G; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2017) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "The effect of mirtazapine on steady-state plasma concentrations of the newer atypical antipsychotics clozapine, risperidone and olanzapine was investigated in 24 patients with chronic schizophrenia." | 7.72 | Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. ( Canale, A; Crucitti, D; D'Arrigo, C; Malara, G; Muscatello, MR; Spina, E; Torre, DL; Zoccali, R, 2003) |
| " The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested by monitoring the BPRS and plasma monoamine metabolites." | 7.68 | Effects of mianserin in chronic schizophrenia. ( Kai, S; Kajimura, N; Mizuki, Y; Suetsugi, M; Ushijima, I; Yamada, M, 1992) |
| "The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested in 20 inpatients with schizophrenia who were receiving fixed doses of neuroleptics." | 7.68 | Effects of mianserin on negative symptoms in schizophrenia. ( Imai, T; Kai, S; Kajimura, N; Kaneyuki, H; Mizuki, Y; Suetsugi, M; Yamada, M, 1990) |
| "Depression is common in schizophrenia and worsens its course." | 6.76 | Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2011) |
| "Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects." | 6.70 | Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Berk, M; Brook, S; Ichim, C, 2001) |
| "Eighteen inpatients with treatment-resistant schizophrenia who had an acute psychotic exacerbation of the disorder received, in a double-blind design, 30 mg/day mianserin (n = 9) or placebo (n = 9) in conjunction with typical neuroleptics [haloperidol (n = 9) or perphenazine (n = 9)]." | 6.70 | Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. ( Aizenberg, D; Bodinger, L; Munitz, H; Shiloh, R; Valevski, A; Weizman, A; Zemishlany, Z, 2002) |
| "Headaches and nausea are the 2 most common adverse effects of electroconvulsive therapy (ECT)." | 6.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| "1." | 5.29 | Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. ( Inanaga, K; Kuniyoshi, M; Miura, C; Nakamura, J, 1994) |
| "Mirtazapine has often been prescribed as add-on treatment for schizophrenia in patients with suboptimal response to conventional treatments." | 5.22 | Mirtazapine in schizophrenia - an undeservedly overlooked option? ( Joffe, G; Terevnikov, V, 2022) |
| "We aimed to evaluate predictors and mediators of enhancing effect of adjunctive mirtazapine on cognition in schizophrenia." | 5.17 | Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation. ( Burkin, M; Chukhin, E; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2013) |
| " In this study, interrelationship of similar metabolic effects of mirtazapine and its earlier reported desirable effects on psychopathology in first-generation antipsychotics (FGAs)-treated schizophrenia were explored." | 5.17 | Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial. ( Burkin, M; Chukhin, E; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2013) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 5.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| "These findings support our previous data on the additive antipsychotic effect of mirtazapine in FGAs-treated schizophrenia." | 5.14 | More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2010) |
| "It has been reported that mirtazapine would be helpful for treating negative symptoms in schizophrenia." | 5.14 | The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. ( Abbasi, SH; Akhondzadeh, S; Behpournia, H; Ghoreshi, A; Raznahan, M; Rezaei, F; Rezazadeh, SA; Salehi, B, 2010) |
| "Mirtazapine added to antipsychotics appears to improve the clinical picture of schizophrenia, including both negative and positive symptoms." | 5.14 | Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2010) |
| "Schizophrenia-diagnosed patients with a prolonged disease and a history of a poor response to numerous antipsychotics, who were at least moderately ill despite their FGAs treatment, received add-on mirtazapine (n=20) or placebo (n=19) in a 6-week double-blind randomized controlled trial (RCT)." | 5.14 | Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2009) |
| "This trial does not confirm previous research supporting the use of mirtazapine adjunctive to atypical antipsychotic treatment for schizophrenia." | 5.14 | Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. ( Berk, M; Bole, F; D'Souza, R; Dodd, S; Gama, CS; Hustig, H; Koopowitz, L; Malloy, H; Monkhouse, A; Piskulic, D; Rowland, C; Sathiyamoorthy, S; Sundram, S, 2009) |
| " In a double-blind placebo-controlled study we examined the effect of add-on mianserin (15 mg/day), an agent with marked 5-HT2A antagonism, on cognitive functioning in 30 chronic hospitalized DSM-IV schizophrenia patients stabilized on typical antipsychotics." | 5.10 | Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. ( Fuchs, C; Gonopolsky, I; Koren, D; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "Thirty neuroleptic-treated patients with schizophrenia were randomly allocated in a double-blind design to receive either mianserin (15 mg/day) or placebo for five days." | 5.09 | Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. ( Fuchs, C; Poyurovsky, M; Schneidman, M; Shardorodsky, M; Weizman, A, 1999) |
| "The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia." | 5.08 | Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. ( Fujikawa, T; Furutani, M; Hayashi, T; Horiguchi, J; Nishikawa, T; Takahashi, T; Tawara, Y; Yamawaki, S; Yano, T; Yokota, N, 1997) |
| "All randomised-controlled trials (RCTs) with useable data focusing on mirtazapine adjunct for people with schizophrenia." | 4.98 | Mirtazapine adjunct for people with schizophrenia. ( Perry, LA; Ramson, D; Stricklin, S, 2018) |
| "To assess the efficacy of mirtazapine as an adjunctive treatment of negative symptoms in patients with chronic schizophrenia via meta-analysis." | 4.91 | Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia. ( Chiapelli, J; Fischer, BA; Himelhoch, S; Reese, C; Vidal, C, 2015) |
| "The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia." | 3.88 | Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. ( Lorenc-Koci, E; Rogóż, Z; Wąsik, A, 2018) |
| "This study randomly assigned FGA-treated patients with schizophrenia to receive either an add-on mirtazapine (n = 20) or a placebo (n = 19) for 6 weeks." | 3.85 | Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics. ( Burkin, M; Joffe, G; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2017) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "The effect of mirtazapine on steady-state plasma concentrations of the newer atypical antipsychotics clozapine, risperidone and olanzapine was investigated in 24 patients with chronic schizophrenia." | 3.72 | Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. ( Canale, A; Crucitti, D; D'Arrigo, C; Malara, G; Muscatello, MR; Spina, E; Torre, DL; Zoccali, R, 2003) |
| "We have previously found that repeated phencyclidine (PCP) treatment enhances the immobility induced by forced swimming and suggested that this behavioral change could be used as a model of the negative symptoms, particularly depression, of schizophrenia." | 3.69 | Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. ( Furukawa, H; Mamiya, T; Nabeshima, T; Noda, Y, 1997) |
| " The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested by monitoring the BPRS and plasma monoamine metabolites." | 3.68 | Effects of mianserin in chronic schizophrenia. ( Kai, S; Kajimura, N; Mizuki, Y; Suetsugi, M; Ushijima, I; Yamada, M, 1992) |
| "The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested in 20 inpatients with schizophrenia who were receiving fixed doses of neuroleptics." | 3.68 | Effects of mianserin on negative symptoms in schizophrenia. ( Imai, T; Kai, S; Kajimura, N; Kaneyuki, H; Mizuki, Y; Suetsugi, M; Yamada, M, 1990) |
| "Depression is common in schizophrenia and worsens its course." | 2.76 | Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase. ( Burkin, M; Joffe, G; Joffe, M; Stenberg, JH; Tchoukhine, E; Terevnikov, V; Tiihonen, J, 2011) |
| "Mirtazapine adjunction was well tolerated and induced a significant improvement in cognitive performance, as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Randolph, 1998) total score and by the subscales for immediate and delayed memory (p<." | 2.73 | Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. ( Biondi, M; Delle Chiaie, R; Fiorentini, S; Salviati, M, 2007) |
| "Mirtazapine is an antidepressant with antagonist properties at 5-HT2A, 5-HT3 and alpha 2 receptors as well as indirect 5-HT1a agonist effects." | 2.70 | Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Berk, M; Brook, S; Ichim, C, 2001) |
| "Eighteen inpatients with treatment-resistant schizophrenia who had an acute psychotic exacerbation of the disorder received, in a double-blind design, 30 mg/day mianserin (n = 9) or placebo (n = 9) in conjunction with typical neuroleptics [haloperidol (n = 9) or perphenazine (n = 9)]." | 2.70 | Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. ( Aizenberg, D; Bodinger, L; Munitz, H; Shiloh, R; Valevski, A; Weizman, A; Zemishlany, Z, 2002) |
| "Buspirone was effective in only two neuroleptic-induced akathisia patients and caused worsening of akathisia in the other two patients." | 2.68 | Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin. ( Poyurovsky, M; Weizman, A, 1997) |
| "The pharmacologic treatment of schizophrenia and bipolar disorder leaves much to be desired." | 2.48 | Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. ( Davis, JM; Torrey, EF, 2012) |
| "Headaches and nausea are the 2 most common adverse effects of electroconvulsive therapy (ECT)." | 2.47 | Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature. ( Huang, KC; Lee, WK; Li, TC; Shiah, IS; Sun, CJ; Tzang, RF, 2011) |
| "1." | 1.29 | Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. ( Inanaga, K; Kuniyoshi, M; Miura, C; Nakamura, J, 1994) |
| " Our quantitative pharmaco-EEG and clinical trials clearly demonstrated the significant value of quantitative EEG in early screening of psychoactive drugs in order to predict their clinical values and effective dosage ranges." | 1.25 | New drug developments in the Netherlands. "Tetracyclic" psychotropic drugs. ( Dincmen, K; Egilmez, S; Itil, TM; Polvan, N; Sungerbey, K, 1974) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.35) | 18.7374 |
| 1990's | 10 (21.74) | 18.2507 |
| 2000's | 14 (30.43) | 29.6817 |
| 2010's | 19 (41.30) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Terevnikov, V | 9 |
| Joffe, G | 9 |
| Perry, LA | 1 |
| Ramson, D | 1 |
| Stricklin, S | 1 |
| Rogóż, Z | 2 |
| Wąsik, A | 1 |
| Lorenc-Koci, E | 1 |
| Vidal, C | 1 |
| Reese, C | 1 |
| Fischer, BA | 1 |
| Chiapelli, J | 1 |
| Himelhoch, S | 1 |
| Caforio, G | 1 |
| Di Giorgio, A | 1 |
| Rampino, A | 1 |
| Rizzo, M | 1 |
| Romano, R | 1 |
| Taurisano, P | 1 |
| Fazio, L | 1 |
| De Simeis, G | 1 |
| Ursini, G | 1 |
| Blasi, G | 1 |
| Nardini, M | 1 |
| Mancini, M | 1 |
| Bertolino, A | 1 |
| Tao, C | 1 |
| Yan, W | 1 |
| Li, Y | 1 |
| Lu, X | 1 |
| Stenberg, JH | 8 |
| Tiihonen, J | 8 |
| Burkin, M | 8 |
| Joffe, M | 7 |
| Berk, M | 2 |
| Gama, CS | 1 |
| Sundram, S | 1 |
| Hustig, H | 1 |
| Koopowitz, L | 1 |
| D'Souza, R | 1 |
| Malloy, H | 1 |
| Rowland, C | 1 |
| Monkhouse, A | 2 |
| Bole, F | 1 |
| Sathiyamoorthy, S | 1 |
| Piskulic, D | 1 |
| Dodd, S | 1 |
| Laika, B | 1 |
| Leucht, S | 1 |
| Heres, S | 1 |
| Schneider, H | 1 |
| Steimer, W | 1 |
| Tchoukhine, E | 4 |
| Abbasi, SH | 1 |
| Behpournia, H | 1 |
| Ghoreshi, A | 1 |
| Salehi, B | 1 |
| Raznahan, M | 1 |
| Rezazadeh, SA | 1 |
| Rezaei, F | 1 |
| Akhondzadeh, S | 1 |
| Cho, SJ | 1 |
| Yook, K | 1 |
| Kim, B | 1 |
| Choi, TK | 1 |
| Lee, KS | 1 |
| Kim, YW | 1 |
| Lee, JE | 1 |
| Suh, S | 1 |
| Yook, KH | 1 |
| Lee, SH | 1 |
| Li, TC | 1 |
| Shiah, IS | 1 |
| Sun, CJ | 1 |
| Tzang, RF | 1 |
| Huang, KC | 1 |
| Lee, WK | 1 |
| Phan, SV | 1 |
| Kreys, TJ | 1 |
| Torrey, EF | 1 |
| Davis, JM | 1 |
| Chukhin, E | 2 |
| Poyurovsky, M | 3 |
| Koren, D | 1 |
| Gonopolsky, I | 1 |
| Schneidman, M | 2 |
| Fuchs, C | 2 |
| Weizman, A | 5 |
| Weizman, R | 1 |
| Zoccali, R | 2 |
| Muscatello, MR | 2 |
| Torre, DL | 1 |
| Malara, G | 1 |
| Canale, A | 1 |
| Crucitti, D | 1 |
| D'Arrigo, C | 1 |
| Spina, E | 2 |
| Orlandi, V | 1 |
| Speca, A | 1 |
| Salviati, M | 2 |
| Biondi, M | 2 |
| Cedro, C | 1 |
| Neri, P | 1 |
| La Torre, D | 1 |
| Di Rosa, AE | 1 |
| Meduri, M | 1 |
| Robertson, VB | 1 |
| Wilson, MS | 1 |
| Zink, M | 1 |
| Knopf, U | 1 |
| Argiriou, S | 1 |
| Kuwilsky, A | 1 |
| Itil, TM | 1 |
| Polvan, N | 1 |
| Dincmen, K | 1 |
| Egilmez, S | 1 |
| Sungerbey, K | 1 |
| Delle Chiaie, R | 1 |
| Fiorentini, S | 1 |
| Kuniyoshi, M | 1 |
| Nakamura, J | 1 |
| Miura, C | 1 |
| Inanaga, K | 1 |
| Oretti, RG | 1 |
| Spurlock, G | 1 |
| Buckland, PR | 1 |
| McGuffin, P | 1 |
| Fitzgerald, LW | 1 |
| Deutch, AY | 1 |
| Gasic, G | 1 |
| Heinemann, SF | 1 |
| Nestler, EJ | 1 |
| Noda, Y | 1 |
| Mamiya, T | 1 |
| Furukawa, H | 1 |
| Nabeshima, T | 1 |
| Hayashi, T | 2 |
| Nishikawa, T | 2 |
| Koga, I | 1 |
| Uchida, Y | 1 |
| Horiguchi, J | 2 |
| Yamawaki, S | 2 |
| Yokota, N | 1 |
| Takahashi, T | 1 |
| Tawara, Y | 1 |
| Yano, T | 1 |
| Furutani, M | 1 |
| Fujikawa, T | 1 |
| Shardorodsky, M | 1 |
| Grinshpoon, A | 1 |
| Valevski, A | 2 |
| Moskowitz, M | 1 |
| Ichim, C | 1 |
| Brook, S | 1 |
| Shiloh, R | 1 |
| Zemishlany, Z | 1 |
| Aizenberg, D | 1 |
| Bodinger, L | 1 |
| Munitz, H | 1 |
| Duggal, HS | 1 |
| Fetchko, J | 1 |
| Zavitsanou, K | 1 |
| Huang, XF | 1 |
| Mizuki, Y | 2 |
| Kajimura, N | 2 |
| Kai, S | 2 |
| Suetsugi, M | 2 |
| Ushijima, I | 1 |
| Yamada, M | 2 |
| Imai, T | 1 |
| Kaneyuki, H | 1 |
| King, DJ | 1 |
| Devaney, NM | 1 |
| Cooper, SJ | 1 |
6 reviews available for mianserin and Schizophrenia
| Article | Year |
|---|---|
Mirtazapine in schizophrenia - an undeservedly overlooked option?
Topics: Antidepressive Agents; Antipsychotic Agents; Humans; Mianserin; Mirtazapine; Schizophrenia | 2022 |
Mirtazapine adjunct for people with schizophrenia.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Chemotherapy, Adjuvant; Humans; Mianserin; M | 2018 |
Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Drug Therapy, Combination; Humans; Mianserin | 2015 |
Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Electroconvulsive Therapy; Fema | 2011 |
Adjunct mirtazapine for negative symptoms of schizophrenia.
Topics: Antidepressive Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Mianserin; Mirtazapi | 2011 |
Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; An | 2012 |
20 trials available for mianserin and Schizophrenia
| Article | Year |
|---|---|
Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; | 2013 |
Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Syner | 2009 |
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Co | 2009 |
Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Drug Therapy, Combination; Executive Fu | 2010 |
The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Double-Blind Method; Female; Humans; | 2010 |
More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychot | 2010 |
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cognition Disorders; Double-Blind Met | 2011 |
More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cognition; Cross-Sectional Studies; D | 2011 |
Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Double- | 2011 |
Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adult; Antipsychotic Agents; Cognition; Cognition Disorders | 2013 |
Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Co | 2013 |
Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Chronic Disease; Cognition Disorders; Double-B | 2003 |
The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Adult; Antipsychotic Agents; Clozapine; Double-Blind Method; Drug Syne | 2004 |
Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Antipsychotic Agents; Brief Psychiatric R | 2007 |
Involvement of the alpha2-adrenergic system in polydipsia in schizophrenic patients: a pilot study.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Clonidine; Drinking Behavior; Female; Human | 1997 |
Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Brief Psychiatric Rating Scale; Double- | 1997 |
Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Buspirone; Female; Humans; Male | 1997 |
Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Double-Blind Method; Female; Humans; Male; Mianserin; Schizophrenia; | 1999 |
Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Double-Blind Method; Drug The | 2001 |
Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Resistance; Drug Ther | 2002 |
20 other studies available for mianserin and Schizophrenia
| Article | Year |
|---|---|
Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Disease Models, Anim | 2018 |
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
Effect of antidepressants on spatial memory deficit induced by dizocilpine.
Topics: Animals; Antidepressive Agents; Cell Count; Citalopram; Cognition; Cognitive Dysfunction; Dizocilpin | 2016 |
Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Drug Therapy, Combination; Female; Hu | 2017 |
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
Topics: Adult; Aged; Benzodiazepines; Cytochrome P-450 CYP1A2; Depressive Disorder; Female; Genotype; Humans | 2010 |
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials | 2003 |
Abnormal prolactin elevation in a schizophrenic patient in treatment with quetiapine and mirtazapine. The role of opioid system.
Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Drug Interactions; Female; Humans; Mianserin; Mirta | 2003 |
Neurotensin receptor agonists and antagonists for schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Data Interpretation, Statistical; Humans; Mianserin; M | 2005 |
A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Comorbidity; Depressive Disorder, Maj | 2006 |
New drug developments in the Netherlands. "Tetracyclic" psychotropic drugs.
Topics: Adjustment Disorders; Anxiety Disorders; Bipolar Disorder; Brain; Clinical Trials as Topic; Dibenzox | 1974 |
Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia.
Topics: Adult; Biogenic Monoamines; Chronic Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1994 |
Lack of effect of antipsychotic and antidepressant drugs on glutamate receptor mRNA levels in rat brains.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Base Sequence; Brain Chemistry; Citalopram; Cl | 1994 |
Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Benzazepines; Cerebral Cortex; Clozapine; Corpus Striatum; Dopamine; | 1995 |
Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depression; Desipramine; Hallucinogens; Hydroxyindoleacetic Acid; Ma | 1997 |
Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Brief Psychia | 2000 |
Serotonin syndrome and atypical antipsychotics.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; | 2002 |
Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study.
Topics: Adult; Aged; Antipsychotic Agents; Binding Sites; Binding, Competitive; Butaclamol; Down-Regulation; | 2002 |
Effects of mianserin in chronic schizophrenia.
Topics: Adult; Biogenic Monoamines; Female; Humans; Male; Mianserin; Middle Aged; Psychiatric Status Rating | 1992 |
Effects of mianserin on negative symptoms in schizophrenia.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Brain; Chronic Disease; Drug Therapy, Combination | 1990 |
Rapid normalization of the dexamethasone suppression test with mianserin.
Topics: Chlorpromazine; Depressive Disorder; Dexamethasone; Haloperidol; Humans; Hydrocortisone; Mianserin; | 1987 |